Posts by tag
adjuvant treatment
Intermittent dosing of exemestane is non-inferior to daily dosing
Giving the aromatase inhibitor (AI) exemestane 25 mg three times weekly was non-inferior to the standard dosing of 25mg daily among study participants who complied with the schedule. The international, multicentric study, which was supported by the US National Cancer…
Melanoma: treatment sequence matters
Patients with metastatic melanoma who received immunotherapy before targeted therapy showed a 20% overall survival advantage at two years versus those receiving targeted therapy first, with immunotherapy after. The final results of the DREAMseq trial, published in the Journal of…
Obesity and cancer: 12 things clinicians and patients should know
The significant link that has been clearly established between obesity and risk of 13 types of cancer means that many patients in the ‘obese’ category can be offered an opportunity to improve their health and their prognosis. Currently, more often…
Immunotherapy plus chemo: benefits in lung cancer neoadjuvant treatment
Adding a check point inhibitor to chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) produced significant improvements of pathological complete response (pCR) in comparison to chemotherapy alone. The CheckMate-816 study, presented at the American Association for Cancer…